<unk> (INN/USAN, trade name Omontys, formerly Hematide), developed by Affymax and Takeda, is an erythropoietic agent, a functional analog of erythropoietin.
It was approved by the U.S. Food and Drug Administration for treatment of anemia associated with chronic kidney disease (CKD) in adult patients on dialysis. On February 23, 2013, Affymax and Takeda issued a press release indicating that they were recalling all batches of<unk>  from the market.
Two randomized controlled trials published in 2013 found that the effectiveness of<unk>  was not inferior to epoetin for patients receiving dialysis (the EMERALD study), or to darbepoetin for patients with chronic kidney disease who were not receiving dialysis (the PEARL study). However, the safety endpoint of cardiovascular events and death was worse for<unk>  than for darbepoetin in the PEARL study.
Peginesatide
Plecanatide
Pegloticase
Drotrecogin alfa
Cerliponase alfa
Ceruletide
Oprelvekin
Sebelipase alfa